Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0167 • ACR Convergence 2024
Epidemiology of Falls in a Diverse Cohort of Adults with SLE
Laura Plantinga¹, Charmayne M. Dunlop-Thomas², Courtney Hoge³, Jinoos Yazdany⁴ and C. Barrett Bowling⁵, ¹University of California, San Francisco, San Francisco, CA, ²Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ³Emory University, Atlanta, GA, ⁴UCSF, San Francisco, CA, ⁵Duke University, Durham, NC
Background/Purpose: While often preventable, falls are a common, costly, and serious outcome in the U.S. population: more than one in four adults ³65 years old…
Abstract Number: 0191 • ACR Convergence 2024
Beyond the Symptoms: Exploring Cognitive Bias in Lupus Diagnosis Within Primary Care
Alyssa Howren¹, Quan Le Tran¹, Sadaf Sediqi¹, Saadiya Hawa², Eleni Linos¹, Titilola Falasinnu³, Yashaar Chaichian¹ and Julia Simard¹, ¹Stanford School of Medicine, Stanford, CA, ²Weiss Memorial Hospital, Chicago, IL, ³Stanford School of Medicine, Palo Alto, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune rheumatic disease whose prognosis varies by race and sex. To understand whether the cognitive processes of…
Abstract Number: 0353 • ACR Convergence 2024
Identifying Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus-Based Approach
Joy Buie¹, Michael Fisher¹, Hannah Tlydsley², Kristen Backor² and Karen Costenbader³, ¹Lupus Foundation of America, Washington, DC, ²Charles River Associates, San Francisco, CA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: Health disparities among racial and ethnic minoritized individuals living with lupus remain a critical public health concern. Challenges related to healthcare affordability, accessibility, and…
Abstract Number: 0442 • ACR Convergence 2024
Anti-U1-RNP Related Pregnancy Loss in Systemic Lupus Erythematosus
Anam Nazir¹, Joshua Reed², Khalid Alghamdi² and Catherine Ivory¹, ¹The Ottawa Hospital, Ottawa, ON, Canada, ²The Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) affects women of childbearing years and confers an increased risk of pregnancy complications. Risk of adverse events in pregnancy is…
Abstract Number: 0618 • ACR Convergence 2024
Comparison of Cell Type-Specific Polygenic Risk in Systemic Lupus Erythematosus Patient and Healthy Controls
Liyoung Kim¹, Vitor Aguiar², Daniela Fernandez-Salinas³, Jeffrey Sparks⁴, Peter Nigrovic¹, Joyce Chang² and Maria Gutierrez-Arcelus², ¹Boston Children's Hospital, Brookline, MA, ²Boston Children's Hospital, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Polygenic risk scores quantify the composite impact of numerous genetic variants to predict disease risk. However, conventional polygenic risk scores have limitations in revealing…
Abstract Number: 0637 • ACR Convergence 2024
Active Implementation of Low Disease Activity State as Treatment Endpoint in a Large Cohort of Adolescents and Young Adults with Childhood Onset Systemic Lupus Erythematosus
Ruby Gotch¹, Yumna Ahmed¹, Robert Wilson¹, Ellie Hawkins¹ and Coziana Ciurtin², ¹University College London Hospital NHS Trust, London, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: Treat-to-target (T2T) strategies are focused on proactive and tailored management of disease activity to minimise damage risk and improve long-term outcomes in SLE across…
Abstract Number: 0655 • ACR Convergence 2024
Relationship Between Patient-Reported Outcomes to Hospitalization in Patients Living with SLE: A Retrospective Cohort Study Utilizing the FORWARD Lupus Registry
Minjee Park¹, Sofia Pedro², Jean-Francois Ricci¹, Kaleb Michaud³ and Patti Katz⁴, ¹Alira Health, Basel, Switzerland, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE, ⁴UCSF, San Rafael, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with diverse symptoms and multisystemic manifestations. Reducing exacerbations (flares), often leading to hospitalization, remains a challenge…
Abstract Number: 0673 • ACR Convergence 2024
BCMA-CD19 Compound CAR-T (cCAR) Safely Provides a Complete Humoral Reset Eliminating All Autoantibodies Resulting in Long-term Medication-Free Complete Remission Among Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients
Yong Yuan¹, Shanzhi He², Wenli Zhang³, Hongyu Zhang⁴, Vincent M DeStefano⁵, Masayuki Wada⁵, Kevin Pinz⁵, Greg Deener⁵, Yu Ma⁶, Min Wang², Fugui Li⁷, Ming Hong¹, Chanjuan Zou², Mingxia Wang², Ling Ding², Yingwen Liang⁸, Yupo Ma⁵ and Weija Wang⁹, ¹Department of Translational Medicine, Zhongshan people's Hospital, Zhongshan, China (People's Republic), ²Department of Rheumatoid Immunology, Zhongshan people's Hospital, Zhongshan, China (People's Republic), ³Department of Hematology, Peking University Shenzhen Hosptial, Shenzhen, China (People's Republic), ⁴Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China (People's Republic), ⁵iCell Gene Therapeutics, Inc., Stony Brook, NY, ⁶iCAR Bio Therapeutics Ltd, Zhongshan, China (People's Republic), ⁷Department of Translational Medicine. Zhongshan people's Hospital, Zhongshan, China (People's Republic), ⁸Department of Translational Medicine, Zhongshan's people Hospital, Zhongshan, China (People's Republic), ⁹Department of Translational Research, Zhongshan people's Hospital, Zhongshan, China (People's Republic)
Background/Purpose: Medication free complete remission (CR) has been elusive in SLE. An open label investigator-initiated trial (IIT) infused SLE/LN patients with a novel cCAR targeting…
Abstract Number: 0897 • ACR Convergence 2024
Dynamic eQTLs from Activated Human B Cells Suggest Cell-state Dependent Effects for GWAS Risk Variants in BLK
Yao Fu, David Murphy, Richard Pelikan, Jeniffer Kelly, Kiely Grundahl, Satish Pasula, Kandice Tessneer and Patrick Gaffney, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex genetic disease in which B cells play a critical role in pathogenesis. Previous genome-wide association studies (GWAS)…
Abstract Number: 1045 • ACR Convergence 2024
Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: Rheumatic diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and systemic lupus erythematosus (SLE) can significantly impact quality of life. This burden extends…
Abstract Number: 1262 • ACR Convergence 2024
The Relationship Between Child Opportunity Index and Burden of Pediatric Systemic Lupus Erythematosus
Ayah Eltoum¹, Livie Timmerman², Melissa Mannion¹ and Emily Smitherman¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Gardendale, AL
Background/Purpose: Outcomes for systemic lupus erythematosus are known to be associated with sociodemographic indicators. The Child Opportunity Index (COI) is a well-validated measure of neighborhood…
Abstract Number: 1483 • ACR Convergence 2024
Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors
SAUMYA TRIPATHY¹, DEBASISH PANDIT², Sarit Pattanaik³, Liza Rajasekhar⁴, VINEETA SHOBHA⁵, Chengappa Kavadichanda⁶, Ashish J Mathew⁷, Parasar Ghosh⁸, Ranjan Gupta⁹, Manish Rathi¹⁰, AVINASH JAIN¹¹, MANOJ PARIDA¹², Bidyut Das¹³ and Amita Aggarwal¹⁴, ¹SCB Medical College, Cuttack, Odisha, India, Cuttack, Orissa, India, ²SJM MCH, Puri, Puri, Orissa, India, ³SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, Orissa, India, ⁴Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India, ⁵ST JOHN'S MEDICAL COLLEGE, BENGALURU, Karnataka, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷Christian Medical College, Vellore, Tamil Nadu, India, ⁸Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁹All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹⁰Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India, ¹¹SMS MCH, JAIPUR, JAIPUR, Rajasthan, India, ¹²SCB MEDICAL COLLEGE, CUTTACK, Cuttack, Orissa, India, ¹³SCB Medical College, Cuttack, Orissa, India, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Infections in SLE are a major cause of morbidity and mortality. The susceptibility to infections in SLE is multifactorial. Immune dysregulation, immunosuppressive drug use and…
Abstract Number: 1500 • ACR Convergence 2024
Work-Related Disability and Function in Systemic Lupus Erythematosus (SLE): Outcomes of an Exploratory Study from Different Canadian Centres
Behdin Nowrouzi-Kia¹, J. Antonio Avina-Zubieta², Mary Fox³, William Shaw⁴, Maggie Ho⁵, Qixuan Li⁵, Catherine Ivory⁶, Paul Fortin⁷, Stephanie Keeling⁸, Jennifer Reynolds⁹, Derek Haaland¹⁰, Janet Pope¹¹, Lily Lim¹², Patti Katz¹³, Murray Urowitz¹⁴, Laura Patricia Whittall Garcia⁵, Dafna Gladman¹⁵ and Zahi Touma¹, ¹University of Toronto, Toronto, ON, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³York University, Toronto, ON, Canada, ⁴University of Connecticut, School of Medicine, Farmington, CT, ⁵University Health Network, Toronto, ON, Canada, ⁶The Ottawa Hospital, Ottawa, ON, Canada, ⁷Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁸University of Alberta, Edmonton, AB, Canada, ⁹UBC, North Vancouver, BC, Canada, ¹⁰The Waterside Clinic, Oro Medonte, ON, Canada, ¹¹University of Western Ontario, London, ON, Canada, ¹²University of Manitoba, Winnipeg, MB, Canada, ¹³UCSF, San Rafael, CA, ¹⁴Self employed, Toronto, ON, Canada, ¹⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) has a significant and long-lasting impact on work outcomes, is a source of long-lasting work disability, and presents challenges with…
Abstract Number: 1516 • ACR Convergence 2024
Diagnostic Performance of Anti-ribosomal P Antibodies in Cerebrospinal Fluid of Neuropsychiatric Systemic Lupus Erythematosus with Diffuse Central Nervous System Manifestations. Experience in a Tertiary Center in Mexico
Marlon Sandino-Bermúdez¹, Erik Cimé-Aké², Jonathan Campos-Guzmán³, Eduardo Briones-García⁴, Emilio G. Lazarini², Carlos Núñez-Álvarez⁵ and Hilda Fragoso-Loyo², ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department., Ciudad de México, Distrito Federal, Mexico, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico
Background/Purpose: Diagnosing neuropsychiatric systemic lupus erythematosus (NPSLE) remains a challenge. The aim of this study was to evaluate the diagnostic performance of anti-ribosomal P antibodies…
Abstract Number: 1534 • ACR Convergence 2024
Use and Safety of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients with Lupus Nephritis and Clinical Indications
April Jorge¹, Kila Panchot², Baijun Zhou², Aakash Patel¹ and Hyon K. Choi³, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have nephroprotective and cardioprotective benefits and may have a role in lupus nephritis (LN) treatment. 2023 EULAR SLE treatment guidelines…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].